Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.39 |
| ▸ | LIG1 | P18858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28885346 | 0.92 | KDM1A (0.41) | MAPTALDH1A1LMNACYP3A4TSHR | |
| SCHEMBL2528047 | 0.86 | MAPT (0.52) | MAPTKDM1AMEN1KMT2ASLC6A3 | |
| SCHEMBL12035589 | 0.86 | MAPT (0.52) | MAPTKDM1AMEN1KMT2ASLC6A3 | |
| SCHEMBL28279218 | 0.85 | OPRK1 (0.44) | MAPTALDH1A1KDM1ARCOR1LIG1 | |
| SCHEMBL27903891 | 0.84 | GAA (0.47) | MAPTALDH1A1LMNATSHRKDM1A | |
| SCHEMBL4133969 | 0.80 | KDM1A (0.44) | LMNAKDM1ARCOR1LIG1RORC | |
| SCHEMBL9989762 | 0.79 | MAPT (0.55) | MAPTKDM1AMEN1KMT2A | |
| SCHEMBL5961926 | 0.79 | MAPT (0.55) | MAPTKDM1AMEN1KMT2A | |
| SCHEMBL8039628 | 0.78 | TSHR (0.47) | ALDH1A1LMNACYP3A4TSHRKDM1A | |
| SCHEMBL28885404 | 0.78 | TUBB4A (0.44) | MAPTALDH1A1CYP3A4TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101945851-B | peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors | ASTRAZENECA AB | 2012-10-31 | — | — | CN | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| CN-101945851-A | Peptidyl nitriles and their use as dipeptidyl peptidase I inhibitors | ASTRAZENECA AB | 2011-01-12 | — | — | CN | disclosed |
| EP-2231597-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | MAPT 3970/4885ALDH1A1 1620/4885LMNA 2051/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | MAPT 3970/4885ALDH1A1 1620/4885LMNA 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.